A Markov model of a cohort of 264,489 Venezuelan 11-year-old girls found the bivalent and quadrivalent HPV vaccines cost-saving compared with screening alone in all scenarios tested.
Published as "Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model". Authors from the Instituto de Efectividad Clínica y Sanitaria in Buenos Aires, Venezuelan public health researchers and two authors from GSK adapted a published model to Venezuela from the health payer's perspective, discounting costs and QALYs at 5%.
Economic evidence for adding HPV vaccine to Venezuela's schedule; WHO's immunisation data still recorded the vaccine as not introduced nationally in 2025.
Shares Ministerio del Poder Popular para la Salud (Venezuela), HPV & HBV vaccination, Cervical cancer.
Shares Ministerio del Poder Popular para la Salud (Venezuela), Cervical cancer.
Shares Ministerio del Poder Popular para la Salud (Venezuela), Cervical cancer.
Shares Ministerio del Poder Popular para la Salud (Venezuela), Cervical cancer.
Shares Ministerio del Poder Popular para la Salud (Venezuela), Cervical cancer.
Shares Ministerio del Poder Popular para la Salud (Venezuela), Cervical cancer.
Shares HPV & HBV vaccination, Cervical cancer.
Shares HPV & HBV vaccination, Cervical cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/